Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion.
Hepatitis B reactivation in hepatitis B surface antigen (HBsAg)-negative and anti-HBsAg antibodies-positive patients is an infrequent complication of chemotherapy, usually with fatal evolution. Here we report an HBsAg-negative patient with a myelodysplastic syndrome, who developed hepatitis B reactivation after chemotherapy and evolved favorably after lamivudine treatment, allowing seroconversion.
Pérez-Grande
Rosa
R
Departamento de Microbiología, Hospital Universitario, 37007 Salamanca, Spain.
Gutiérrez-Zufiaurre
Nieves
N
Muñoz-Criado
Santiago
S
Blázquez de Castro
Ana M
AM
Vázquez López
Lourdes
L
González San Martín
Francisco
F
García Rodríguez
Jose Angel
JA
Muñoz Bellido
Juan Luis
JL
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis* / Q000188:drug therapy*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D019259:Lamivudine / Q000627:therapeutic use*
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D007166:Immunosuppressive Agents; D019259:Lamivudine